A detailed history of Daiwa Securities Group Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 1,810 shares of BNTX stock, worth $187,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,810
Previous 1,925 5.97%
Holding current value
$187,443
Previous $155,000 38.71%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$78.36 - $124.66 $9,011 - $14,335
-115 Reduced 5.97%
1,810 $215,000
Q2 2024

Aug 07, 2024

BUY
$80.36 - $102.87 $125,522 - $160,682
1,562 Added 430.3%
1,925 $155,000
Q1 2024

May 02, 2024

SELL
$88.96 - $112.35 $2,668 - $3,370
-30 Reduced 7.63%
363 $33,000
Q4 2023

Jan 31, 2024

BUY
$90.91 - $112.75 $5,090 - $6,314
56 Added 16.62%
393 $41,000
Q2 2023

Jul 31, 2023

SELL
$102.58 - $129.66 $3,385 - $4,278
-33 Reduced 8.92%
337 $36,000
Q1 2023

May 02, 2023

SELL
$122.57 - $153.67 $254,945 - $319,633
-2,080 Reduced 84.9%
370 $46,000
Q4 2022

Feb 06, 2023

BUY
$118.43 - $186.05 $35,884 - $56,373
303 Added 14.11%
2,450 $368,000
Q3 2022

Nov 02, 2022

BUY
$127.65 - $183.11 $232,195 - $333,077
1,819 Added 554.57%
2,147 $290,000
Q2 2022

Aug 09, 2022

SELL
$123.25 - $186.24 $215,934 - $326,292
-1,752 Reduced 84.23%
328 $49,000
Q1 2022

Apr 29, 2022

BUY
$126.25 - $231.85 $15,781 - $28,981
125 Added 6.39%
2,080 $355,000
Q4 2021

Feb 03, 2022

BUY
$216.64 - $362.52 $14,731 - $24,651
68 Added 3.6%
1,955 $504,000
Q3 2021

Nov 05, 2021

BUY
$205.93 - $447.23 $356,258 - $773,707
1,730 Added 1101.91%
1,887 $515,000
Q2 2021

Aug 06, 2021

BUY
$113.32 - $241.49 $906 - $1,931
8 Added 5.37%
157 $35,000
Q1 2021

May 03, 2021

BUY
$85.73 - $119.5 $2,057 - $2,868
24 Added 19.2%
149 $16,000
Q4 2020

Feb 04, 2021

BUY
$72.71 - $129.54 $9,088 - $16,192
125 New
125 $10,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $25.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.